Table 3.
Treatment and outcomes in eyes with LACNP
| Number (percentage) | |
|---|---|
| Laser burns in PRP | 1798.0 ± 724.9 |
| Macular grid laser | 5 (11.6%) |
| Follow-up duration (months) | 12.4 ± 16.7 |
| logMAR BCVA | |
| Improved | 12 (27.9%) |
| Stable | 7 (16.3%) |
| Deteriorated | 24 (55.8%) |
| Complications | |
| VH | 12 (27.9%) |
| TRD | 6 (14.0%) |
| NVG | 9 (20.9%) |
| Intervention | |
| Anti-VEGF agents | 17 (39.5%) |
| PPV surgery | 11 (25.6%) |
| Anti-glaucoma surgery | 4 (9.3%) |
Abbreviations: PRP pan-retinal photocoagulation, BCVA best corrected visual acuity, FFA fluorescence fundus angiography, VEGF vascular endothelial growth factor, PPV pars plana vitrectomy, VH Vitreous hemorrhage, TRD Tractional retinal detachment, NVG Neovascular glaucoma. Data are mean ± SD